Teva Pharmaceutical Industries acquired Barr Pharmaceuticals for $39.90 cash plus 0.6272 Teva ADRs per share (~$7.5 billion equity value plus $1.5 billion assumed debt), gaining Barr's US generics portfolio including first-to-file ANDA positions, PLIVA's European operations, and a growing women's health branded portfolio (Plan B, Seasonique).
Key facts
AnnouncedJul 18, 2008
ClosedDec 23, 2008
Deal value$7.5B
Deal typeAcquisition/Merger
Therapeutic areaNeurology, Women's Health
IndicationsGeneric pharmaceuticals, Women's health
Key assetsBarr US generics portfolio, PLIVA European operations, Plan B (emergency contraception), Seasonique (oral contraceptive), First-to-file ANDA positions, levonorgestrel (Plan B), levonorgestrel/ethinyl estradiol (Seasonique), Generic portfolio